Systemic Xerostomia Agents

Although not designated as a formal, standalone classification term by the U.S. Food and Drug Administration, systemic xerostomia agents—more formally classified as systemic sialogogues or oral cholinergic agonists—refer to systemically administered medications used to treat severe dry mouth These agents, primarily pilocarpine and cevimeline, act by stimulating muscarinic acetylcholine receptors within functional exocrine tissues to induce endogenous saliva production They are clinically indicat...

Although not designated as a formal, standalone classification term by the U.S. Food and Drug Administration, systemic xerostomia agents—more formally classified as systemic sialogogues or oral cholinergic agonists—refer to systemically administered medications used to treat severe dry mouth They are clinically indicated to alleviate oral dryness in autoimmune disorders, most notably Sjögren disease, and to manage radiation-induced salivary gland hypofunction following head and neck cancer thera...

Although not designated as a formal, standalone classification term by the U.S. Food and Drug Administration, systemic xerostomia agents—more formally classified as systemic sialogogues or oral cholinergic agonists—refer to systemically administered medications used to treat severe dry mouth

These agents, primarily pilocarpine and cevimeline, act by stimulating muscarinic acetylcholine receptors within functional exocrine tissues to induce endogenous saliva production

They are clinically indicated to alleviate oral dryness in autoimmune disorders, most notably Sjögren disease, and to manage radiation-induced salivary gland hypofunction following head and neck cancer therapy